🏠 Price Tracker 📖 Dictionary 🧮 Calculators 📋 Vendor Apply 🎙️ Book the Live 📣 Advertise ⚠️ Disclaimer 👤 Account

FOXO4-DRI

Longevity

A senolytic peptide that selectively triggers apoptosis in senescent cells while sparing healthy tissue.

Half-life
~8–12 hours
Research dose
5mg/kg (animal studies)
Frequency
3× weekly in research cycles
Routes
IP or SubQ injection

How it works

Retro-inverso D-amino acid peptide that penetrates cells and disrupts the interaction between FOXO4 (a transcription factor overexpressed in senescent cells) and p53. In normal cells, FOXO4-p53 interaction is low. In senescent cells, FOXO4 sequesters p53 in the nucleus to prevent apoptosis — FOXO4-DRI breaks this interaction, freeing p53 to trigger programmed cell death selectively in senescent cells.

Research uses

Senolytic therapy research
Healthspan extension studies
Tissue rejuvenation models
Ageing biology
Cancer biology (senescence)

Research notes

Published in Cell (2017) by de Keizer et al., FOXO4-DRI reversed multiple age-related phenotypes in fast-ageing and naturally aged mice — including restoring fur density, fitness, and kidney function — without apparent toxicity to normal tissues.

Senolytics (senescent cell-clearing agents) represent a growing frontier in ageing biology. FOXO4-DRI's high selectivity for senescent versus normal cells distinguishes it from broader senolytics like dasatinib/quercetin.

Storage

❄️Freeze lyophilized powder
🌡️Refrigerate once reconstituted
📅Use within 3 weeks

Ready to compare FOXO4-DRI prices?

Real-time prices across 14 vendors with discount codes already applied.

Compare Prices →

Also in the dictionary